Immunohematopoietic stem cell transplantation in Cape Town: A ten-year outcome analysis in adults

Hematology/ Oncology and Stem Cell Therapy

Volumn 2, Issue 2, 2009, Pages 320-332

  Wood, Lucille ^a,b   Haveman, Jonathan ^c   Juritz, June ^c   Waldmann, Herman ^d   Hale, Geoffrey ^d   Jacobs, Peter ^a,b,c,e  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Department of Haematology and Bone Marrow Transplantation Unit   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLIZINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYUREA; IMATINIB; LYMPHOCYTE ANTIBODY; MELPHALAN; METHYLPREDNISOLONE; METOCLOPRAMIDE; NAVELBINE; PARACETAMOL; PHENOBARBITAL; RITUXIMAB; SEROTONIN ANTAGONIST; UNINDEXED DRUG; VALACICLOVIR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APHERESIS; APLASIA; ARTICLE; BLOOD; CANCER RADIOTHERAPY; CELL POPULATION; CHRONIC GRANULOCYTIC LEUKEMIA; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GENDER; GRAFT FAILURE; HAIRY CELL LEUKEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SKIN LYMPHOMA; SURVIVAL; TREATMENT DURATION; VIRUS INFECTION; ALLOTRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; SOUTH AFRICA; STANDARDS; SURVIVAL RATE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOUTH AFRICA; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953670136     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1658-3876(09)50020-9     Document Type: Article

References (160)

1. Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007;109:2256-2262. (Pubitemid 46348231)
2. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica 2007;92:11-18. (Pubitemid 46232653)
3. Grunebaum E, Mazzolari E, porta F, Dallera D, Atkinson A, Reid B, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006;295:508-518.
4. Rovelli AM, Steward CG. Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: open issues and future directions. Bone Marrow Transplant 2005;35 Suppl 1: S23-S26.
5. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-4254. (Pubitemid 47554249)
6. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107:1688-1695. (Pubitemid 43242410)
7. Ansell SM, Armitage JO. Management of Hodgkin lymphoma. Mayo Clin proc 2006;81:419-426.
8. Vignot S, Mounier N, Larghero J, Brice P, Quero L, de Bazelaire C, et al. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. Cancer 2007;109:60-67. (Pubitemid 46127201)
9. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006;107:3058-3064.
10. Bruno B, Sorasio R, patriarca F, Montefusco V, Guidi S, Busca A, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 2007;78:330-337.
11. Lotz JP, Cure H, Janvier M, Asselain B, Morvan F, Legros M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005;41:71-80. (Pubitemid 40036610)
12. Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom 2007;72:291-298. (Pubitemid 350194346)
13. papageorgiou SG, Castleton A, Bloor A, Kottaridis PD. allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006;38:721-727.
14. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576-4583.
15. Chao NJ. Minors come of age: minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant 2004;10:215-223.
16. Borrill V, Schlaphoff T, du Toit E, Marx M, Wood L, Jacobs P. The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. Hematology 2008;13:210-214.
17. Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 2004;34:1-12. (Pubitemid 39022951)
18. Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M, et al. Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes. Bone Marrow Transplant 2004;33:729-734. (Pubitemid 38499927)
19. Antin JH. Acute graft-versus-host disease: inflammation run amok? J Clin Invest 2001;107:1497-1498.
20. Fraser CJ, Baker KS. The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007;138:131-145. (Pubitemid 46976332)
21. Alamo J, Shahjahan M, Lazarus HM, de Lima M, Giralt SA. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant 2005;36:475-479. (Pubitemid 43118140)
22. Mehta J, Singhal S. Rigorous administration of methotrexate and outcome of allogeneic blood stem cell transplantation. Bone Marrow Transplant 2007;39:243-244. (Pubitemid 46243270)
23. Hendriks MP, Blijevens NMA, Schattenberg AVMB, Burger DM, Donnelly JP. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:521-525.
24. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, et al. Cyclosporin a and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005;105:3951-3955. (Pubitemid 40656142)
25. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM and PBSC transplant patients. Bone Marrow Transplant 2002;30:287-295.
26. Afessa B, Tefferi A, Dunn WF, Litzow MR, Peters SG. Intensive care unit support and acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit Care Med 2003;31:1873-1875. (Pubitemid 36714227)
27. Foster Lw, McLellan LJ, Rybicki LA, Dabney J, Welsh E, Bolwell BJ. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals. Bone Marrow Transplant 2006;37:223-228. (Pubitemid 43108817)
28. Parker JR, Taylor SP, Manuel G, Jacobs P. Intramedullary bone marrow reconstitution in the rabbit. S Afr J Surg 1975;13:186-187.
29. Jacobs P. Effect of cyclosporine A on the incidence of graft-versus-host disease (GVHD) and survival of rabbits following allogeneic bone marrow transplantation. In: Baum SJ, Ledney GD, Khan A (eds). Experimental hematology today 1981. Basel: Karger, 1981:87-96.
30. Jacobs P, Wood L. Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa - the historical and scientific perspective. Bone Marrow Transplant 2008;42 Suppl 1:S125-S132.
31. Wood L, Hester JP, Jacobs P. Apheresis - from theory to practice. CME 1993;11:1127-1131.
32. Barendse G, Tailford R, Wood L, Jacobs P. The effect of peptide stimulation on haematopoietic stem cell mobilisation including engraftment characteristics and a note on donor side effects. Transfus Apheresis Sci 2005;32:105-116. (Pubitemid 40292821)
33. Takeyama K, Ohto H. PBSC mobilization. Transfus Apher Sci 2004;31:233-243.
34. Jacobs P, Wood L, Waldmann H, Hale G. Ex-vivo T-cell depletion by exposure to Campath monoclonal antibodies in haematopoietic stem cell allografting: a fifteen-year single team experi- ence. 2nd South African Haematopoietic Stem Cell Transplantation Symposium, 13th-14th Febr 2004, Rosebank, Johannesburg.
35. Jacobs P. Rationale and influence of cyclosporin A donor pre-treatment. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-vs.-Host Disease. Immunology, pathophysiology and treatment. New York: Marcell Dekker; 1990.p.355-369.
36. Hale G, Waldmann H, for CAMPATH Users. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996;17:305-308.
37. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, novitzky N, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69-76.
38. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994;13:763-769. (Pubitemid 24195793)
39. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69-76. (Pubitemid 30456111)
40. Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, et al. CAMPATH-1 antibodies in stem-cell transplantation. The CAMPATH Users. Cytotherapy 2001;3:145-164.
41. Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-1711.
42. Chakrabarti S, Hale G, Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplant proc 2004;36:1225-1227.
43. Ruff P, Schlaphoff T, du Toit E, Heyns A, on behalf of the Board of the South african Bone Marrow Registry. The South African Bone Marrow Registry (SABMR) and allogeneic bone marrow transplantation. S Afr Med J 2008;98:516-520.
44. Confer DL. The National Marrow Donor Program: meeting the needs of the medically underserved. Cancer 2001;91 Suppl.1:274-278.
45. Loberiza FR Jr, Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant 2003;31:417-421.
46. Mesnil F, Jouet JP, Tuppin P, Vernant JP, Golmard JL. Evaluation of centre and period effects in allogeneic hematopoietic stem cell transplantation in France. Bone Marrow Transplant 2004;34:645-651. (Pubitemid 39341546)
47. Wood L, Juritz J, Havemann J, Lund J, Waldmann H, Hale G. Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town. Hematol Oncol Stem Cell Ther 2008;1:80-89.
48. Jacobs P, Wood L. Immunohaematopoietic stem cell transplantation - introduction and 35 years of development in South Africa - the historical and scientific perspective. International Congress on Bone Marrow and Stem Cell Transplantation, 13-15 november 2007, Riyadh, Saudi Arabia.
49. Jacobs P, Wood L. The history and achievements of haematology in Cape Town: a confluence of ideologies. [Forthcoming]
50. Barge RMY, Starrenburg CWJ, Falkenburg JHF, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006;37:1129-1134.
51. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005;104:205-212. (Pubitemid 40847770)
52. Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005;105:2979-2987.
53. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. The acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000;355:1393-1398. (Pubitemid 30215961)
54. du Toit ED, Schlapphoff TEA, Jacobs P. South African Bone Marrow Registry (SABMR): a ten year review. 41st Annual Congress of the Federation of South African Societies of Pathology (FSASP). 1-4 July 2001, Cape Town.
55. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopioietic stem cell transplantation: focus on the use of cord blood products. The Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). Bone Marrow Transplant 2008;41:687-705.
56. Oertel J, Huhn D. Immunocytochemical methods in haematology and oncology. J Cancer Res Clin Oncol 2000;126:425-440.
57. Kern W, Voskova D, Schnittger S, Schoch C, Hiddemann W, Haferlach T. Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Hematol J 2004;5:410-418. (Pubitemid 39359277)
58. Kolialexi A, Tsangaris GT, Kitsiou S, Kanavakis E, Mavrou A. Impact of cytogenetics and molecular cytogenetics studies on hematologic malignancies. Anticancer Res 2005;25:2979-2983. (Pubitemid 41044690)
59. Kremer M, Quintanilla-Martinez L, Nährig J, von Schilling C, Fend F. Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. Virch Archiv 2005;447:920-937. (Pubitemid 41719547)
60. Solomon D, Jacobs P. Bone densitometry - role of quantitative computed tomography. S Afr Med J 2002;92:486. (Pubitemid 34906617)
61. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
62. Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:599-608.
63. Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant 2004;34:257-266. (Pubitemid 39136833)
64. Hendriks MGJ, Schouten HC. Quality of life after stem cell transplantation: a patient, partner and physician perspective. Eur J Intern Med 2002;13:52-56. (Pubitemid 34139942)
65. Jacobs P, Wood L. Haematology at Constantiaberg Medi-Clinic: information booklet. Plumstead: Constantiaberg Medi-Clinic, 2005.
66. Haematology Department & Bone Marrow Transplant Unit: Guidelines for patients. Plumstead: Constantiaberg Medi-Clinic, 2005.
67. Timmers GJ, Dijstelbloem Y, Simoons-Smit AM, van Winkelhoff AJ, Touw DJ, Vandenbroucke-Grauls CMJE, Huijgens PC. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant 2004;33:847-853. (Pubitemid 38519247)
68. Aker SN, Lenssen P, Darbinian J, Cheney CL, Cunningham B. Nutritional assessment in the marrow transplant patient. Nutr Supp Serv 1983;3(10):22-26.
69. Roila F, Garassino M, Fatigoni S. New antiemetic treatments. Ann Oncol 2007;18 Suppl 9: ix43-ix47.
70. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143-1150. (Pubitemid 350007026)
71. Geller RB, Gilmore CE, Dix SP, Lins LS, Topping DL, Davidson TG, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 1995;50:167-172.
72. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, starified by disease severity. Clin Infect Dis 2007;45:302-307.
73. Chernobelski P, Lavrenkov K, Rimar D, Riesenberg K, Schaeffer F, Ariad S, et al. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients. Chemotherapy 2006;52:185-189. (Pubitemid 43882417)
74. Viscoli C, Cometta A, Kern WV, Bock R, paesmans M, Crokaert F, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006;12:212-216.
75. Maharom P, Thamlikitkul V. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate. J Med Assoc Thai 2006;89 Suppl 5:S118-S124. (Pubitemid 46193140)
76. Bonon SHA, Menoni SMF, Rossi CL, De Souza CA, Vigorito AC, Costa DB, Costa SCB. Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. J Infect 2005;20:130-137.
77. Avery RK. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved? Am J Transplant 2007;7:2062-2063.
78. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transplant 2006;12:112-116.
79. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. The valganciclovir in Solid Organ Transplant Study Group. Transplantation 2005;79:1477-1483. (Pubitemid 40847577)
80. Taegtmeyer AB, Halil O, Bell AD, Carby M, Cummins D, Banner NR. neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation 2005;80:127-130. (Pubitemid 40980905)
81. Curran M, Noble S. Valganciclovir. Drugs 2001;61:1145-1150.
82. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-3167. (Pubitemid 47218066)
83. Heuser M, Ganser A, Bokemeyer C. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. The American Society of Clinical Oncology, National Comprehensive Cancer Network, European Organization for Research and Treatment of Cancer. Semin Hematol 2007;44:148-156. (Pubitemid 47031224)
84. Spiess BD. Red cell transfusions and guidelines: a work in progress. Hematol Oncol Lin North Am 2007;21:185-200. (Pubitemid 46135906)
85. Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringden O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005;45:1064-1072. (Pubitemid 40935003)
86. Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, et al. Efficacy of prophylactic transfusions using single donor apheresis platelet versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40:461-464. (Pubitemid 47288226)
87. Norfolk DR, Seghatchian J. pharmacological therapies to minimise platelet transfusion. Transfus Sci 2000;22:149-153.
88. Bond R, Wood L, Jacobs P, Kernoff LM. Platelet collection using IBM 2997 cell separator. J Clin Apheresis 1985;2:258-261.
89. Wood L, Jogessar V, Ward P, Jacobs P. Estimation and predictive use of the corrected count increment - a proposed clinical guideline. Transfus Apher Sci 2005;32:117-124. (Pubitemid 40292822)
90. du Toit JMG, Kaftansky R, Wood L, Jacobs P. A risk-to-benefit analysis for central venous catheters. Transfus Sci 1996;17:379-383.
91. Jacobs P, Wood L, du Toit A, Baker PM. Salvaging the indwelling central venous line: a technical note. Transfus Apher Sci 2002;27:13-16.
92. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters - a reappraisal of the evidence. Br J Cancer 2006;94:189-194. (Pubitemid 43151533)
93. Hurley CK, Wade JA, Oudshoorn M, Middleton D, Kukuruga D, naverrete C, et al. Histocompatibility testing guidelines for hematopoetic stem cell transplantation using volunteer donors: report from The World Marrow Donor Association. Bone Marrow Transplant 1999;24:119-121.
94. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 2004;11:386-391. (Pubitemid 39491431)
95. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2196 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
96. Malhotra P, Varma S, Varma N, Kumari S, Das R, Jain S, et al. Outcome of adult acute lymphobastic eukemia with BFM protocol in a resource-constrained setting. Leuk Lymphoma 2007;48:1173-1178. (Pubitemid 47009207)
97. Jacobs P. The epipodophyllotoxin Vp16-213 in combination chemotherapy for adults with acute nonlymphoblastic leukaemia. Hämatol Bluttransfus 1985;29:70-74.
98. Jacobs P, Dubovsky DW, Wood L. In adult acute nonlymphoblastic leukaemia extended maintenance chemotherapy has no benefit. Am J Hematol 1984;16:255-265.
99. a (Ab-str 13).
100. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653. (Pubitemid 40446252)
101. Jabour E, Cortes J, Kantarjian H. Optimal firstline treatment of chronic myeloid leukemia: how to use imatinib and what role for newer drugs? Oncology 2007;21:653-662.
102. Raemaekers J, Kluin-nelemans H, Teodorovic I, Meerwaldt C, Norrdijk E, Thomas J, et al. The achievements of the EORTC Lymphoma Group. Eur J Haematol 2002;38:S107-S113.
103. Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. The EORTC Lymphoma Group. Eur J Haematol Suppl 2005;66:135-140.
104. Draube A, Behringer K, Diehl V. Germans Hodgkin's Lymphoma Study Group trials: lessons learned from the past and current strategies. Clin Lymphoma Myeloma 2006;6:458-468. (Pubitemid 44043535)
105. Nogova L, Reineke T, Brilliant C, Soeniawski M, Rüdiger T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;20:434-439. (Pubitemid 351171696)
106. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G , et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia working Party. J Clin Oncol 2005;23:9219-9226.
107. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. The International Myeloma Working Group. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
108. Fosså A, Muer M, Kasper C, Welt A, Seeber S, Nowrousian MR. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 1998;12:422-426. (Pubitemid 28138228)
109. Novitzky N, Wood L, Jacobs P. Treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Am J Hematol 1991;36:227-234.
110. Novitzky N, Mobara G, Jacobs P. Antilymphocyte globulin and high-dose methylprednisolone improve survival in patients with aplastic anaemia without additional financial costs. S Afr Med J 1992;81:254-257.
111. Dincol G, Aktan M, Diz-Kücükkaya R, Yavuz S, Nalcaci M, Oztürk S, et al. Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin a, methylprednisolone, and granulocyte colont-stimulating factor. Am J Hematol 2007;82:783-786. (Pubitemid 350194505)
112. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the polish adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:3672-3675. (Pubitemid 46641714)
113. Hoppe RT. Mycosis fungoides: radiation therapy. Dermatol Ther 2003;16:347-354.
114. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology 2007;21 Suppl 1:33-40.
115. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, apisanthanarax N. phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51-58. (Pubitemid 44322770)
116. Ure UB, AR MC, Salihoglu A, Gunter SI, baran A, Ohuz O, et al. alemtuzumab in Sezary syndrome: efficient but not innocent. Eur J Dermatol 2007;17:525-529. (Pubitemid 350207165)
117. Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006;24:718-725. (Pubitemid 44836176)
118. Keating M, Coutré S, Rai K, -sterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220-227.
119. Giné E, Moreno C, Esteve J, Montserrat E. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Pract Res Clin Haematol 2007;20:529-543. (Pubitemid 47250496)
120. Hayhurst M, Banfield W, Wood L, Jacobs P. Complications after haematopoietic stem cell grafting are not reliably predicted by pulmonary function tests. 41st Annual Congress of the Federation of South African Societies of Pathology (FSaSp). 1-4 July 2001, Cape Town.
121. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:429-435. (Pubitemid 40403343)
122. Solomon D, Jacobs P. Bone densitometry - role of quantitative computed tomography. S Afr Med J 2002;92:486. (Pubitemid 34906617)
123. Taskinen M, Saarinen-pihkala UM, Hovi L, Venntenranta K, Mäkitie O. Bone health in children and adolescents after allogeneic stem cell transplantation. Cancer 2007;110:442-451.
124. Ravasco P, Camilo ME, Gouveia-Oliveira A, Adam S, Brum G. A critical approach tu nutritional assessment in critically ill patients. Clin Nutr 2002;21:73-77. (Pubitemid 34257515)
125. Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant 2002;32:715-721. (Pubitemid 37258628)
126. Arfons LM, Lazarus HM. Total parenteral nutrition and hematopoietic stem cell transplantation: an expensive placebo? Bone Marrow Transplant 2005;36:281-288.
127. Kersting S, Koomans HA, Hené RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007;39:359-365. (Pubitemid 46403928)
128. Sakata-Yanagimoto M, Kanda Y, Akagawa M, Asano-Mori K, Kandabashi K, Izutsu K, et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:1043-1047. (Pubitemid 38744792)
129. Uderzo C, pillon M, Corti P, Tridello G, Tana F, Zintl F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graftversus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effect Working Parties. Bone Marrow Transplant 2007;39:667-675.
130. Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2008;21:579-596.
131. Chen X, Handgretinger R, Hale GA. Molecular monitoring of immune reconstitution after haploidentical stem cell transplantation. Curr Stem Cell Res 2008;3:75-78. (Pubitemid 352024852)
132. Horning SJ. Follow-up of adult cancer survivors: new paradigms for survivorship care planning. Hematol Oncol Clin North Am 2008;22:201-210.
133. Gilbert SM, Miller DC, Hollenbeck BK, Montie JE, Wei JT. Cancer survivorship: challenges and changing paradigms. J Urol 2008;179:431-438.
134. a. (abstract)
135. andersson B, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002;8:145-154.
136. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BeaC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008;87:43-48. (Pubitemid 350182540)
137. Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, papdopoulos EB, Small TN, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007;13:1313-1323.
138. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39-44. (Pubitemid 32229501)
139. Jacobs P, Wood L, Horak S. Collection and cryopreservation of human stem and progenitor cells for bone marrow transplantation. J Clin Apheresis 1991;6:54-58.
140. Calmels B, Lemarié C, Esterni B, Malugani C, Charbonniere A, Coso D, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfuion 2007;47:1268-1275. (Pubitemid 46934320)
141. Jacobs p, Dubovsky D, Smith S, Randall G, Bracher M. Bone marrow culture in vitro: a technique for analysis and permanent recording of cel- lular composition. Exp Hematol 1979;7:177-182.
142. Novitzky N, Jacobs P. Marrow stem cell and stroma cell function in aplastic anaemia. Br J Haematol 1991;79:531-533.
143. Podesta M, Piaggio G, Pitto A, Zocchi E, Soracco M, Frassoni F, et al. Modified in vitro conditions for cord blood-derived long-term culture-initiating cells. Exp Hematol 2001;29:309-314. (Pubitemid 32220122)
144. Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: e reappraisal. Ann Oncol 2005;16 Suppl 4:iv132-iv135. (Pubitemid 43084960)
145. Levy GA. C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral(r) formulation. BioDrugs 2001;15:279-290. (Pubitemid 32634789)
146. Clinical guidelines for the use of blood products in South Africa. The Medical Directors of the South African National Blood Services, editors. 4th ed. Weltevreden Park: SANBS, 2008.
147. Fuchs M, Scheid C, Schulz A, Diehl V, Sohngen D. Trimethoprim sulfamethoxazole prophylaxis impairs function of mobilised autologous peripheral blood stem cells. Bone Marrow Transplant 2000 ;26 :815-816. (Pubitemid 30806760)
148. Colby C, Mcafee SL, Sackstein R, Finkelstein DM, Fishman JA, Spitzer TR. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocuystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:897-902. (Pubitemid 29500352)
149. Vollmer RT. Multivariate statistical analysis for pathologists. Part I, the logistic model. Am J Clin pathol 1996;105:115-126. (Pubitemid 26024776)
150. Kaplan EL, Meier p. Nonparametric estimation from incomplete observations. J Am Statist Ass 1958;53:457-481.
151. Takatsuka H, Takemoto Y, Yamada S, Wada H, Tamura S, Fujimori Y, et al. Complication after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant 2000;26:419-426. (Pubitemid 30649558)
152. Haire WD. Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation. Crit Care Med 2002;30 Suppl:S257-S262.
153. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. The Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). Bone Marrow Transplant 2008;41:687-705.
154. Jacobs P, Wood L. Immunohaematopoietic stem cell transplantation in South Africa - the first 40 years: an experimental and clinical model for approaching restorative medicine. The Specialist Forum 2006;6(5):34-43.
155. Sissolak G, Abayomi EA, Jacobs P. AIDS defining lymphomas in the era of highly antiretroviral therapy (HAART) - an African perspective. Transfus Apher Sci 2007;37:63-70. (Pubitemid 47593004)
156. Pamphilon D, Mackinnon S, Nacheva E, Russell N, Wilson K, Clay, M, et al. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006;38:699-700. (Pubitemid 44669686)
157. Gahrton G, Van Rood JJ, Oudshoorn M. The world Marrow Donor association (WMDA): its goals and activities. Bone Marrow Transplant 2003;32:121-124. (Pubitemid 36903433)
158. Hurley CK, Wade JA, Oudshoorn M, Middleton D, Kukuruga D, Navarrete C, et al. Histocompatibility testing guidelines for hematopoietic stem cell transplantation usinf volunteer donors: report from The World Marrow Donor Association. The Quality Assurance and Donor Registries Working Group of the World Marrow Donor Association. Bone Marrow Transplant 1999;24:119-121. (Pubitemid 29351824)
159. Samson D, Slaper-Cortenbach I, Pamphilon D, McGrath E, McDonald F, Urbano IA. Current status of JACIE accreditation in Europe: a special report from the Joint Accreditation Committee of the ISCT and the EBMT (JACIE). Bone Marrow Transplant 2007;39:133-141. (Pubitemid 46178747)
160. Confer D, Robinett P. The US national Marrow Donor Program roles in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant 2008;42 Suppl 1:S3-S5.